Anzu Partners collects $130m for third fund

Anzu Partners has raised $130 million for its third venture fund.

Anzu Partners has raised $130 million for its third venture fund. The target is $300 million. The fund will invest in early-stage “breakthrough” tech companies.


BOSTON & SAN DIEGO & TAMPA, Fla. & WASHINGTON–(BUSINESS WIRE)–Anzu Partners, an investment firm that focuses on early stage industrial and life science technology companies, today announced that its third venture fund has $130M in commitments to date toward a $300M target size.

Anzu’s Fund III will invest in early-stage breakthrough technology companies that can shape and enable high growth sectors that are essential to prosperity, productivity, and sustainability. The fund’s investors include public and private institutions, single and multifamily offices, and individuals across the U.S. and overseas.

Since its founding in 2014, Anzu Partners has grown into a robust investment firm with over 50 team members, and approximately $935M in strategic assets across several funds and strategies, including two existing oversubscribed venture funds (Fund 1 $128M, Fund II $190M), a $425M Special Purpose Acquisition Company (“SPAC”), and a series of special purpose vehicles. Since the close of Fund II, Debrah Herman, Dr. John Ho, and most recently, international investment banker William H. Strong, have joined Managing Partners David Michael, David Seldin, and Whitney Haring-Smith on Anzu’s leadership team.

Anzu will build on its existing portfolio of over 25 companies with the launch of Fund III. The firm continues to focus on identifying and supporting teams pioneering innovations that address major global challenges ranging from next-generation manufacturing to therapy discovery. For example:

6K has developed an advanced materials production platform to disrupt traditional solid-state and chemical synthesis production processes
Niron Magnetics has developed rare-earth free magnets for a more sustainable electric economy

InterVenn Biosciences has developed a proprietary glycoproteomic platform that enables a powerful new class of cancer diagnostics based on glycobiology

“Innovations in life sciences and industrial technologies continue to proliferate since the launch of our first two funds, and we see an even greater opportunity to work with early-stage companies and commercialize their scientific breakthroughs,” said David Michael, Managing Partner, Anzu Partners. “Not only do we provide capital, we also utilize our technically-oriented team of investment and operational professionals to offer support on financial management, operations, talent development, global connectivity, strategy, and more, to truly serve as a partner. We are excited about the future of Anzu Partners and our portfolio as we begin to explore the already active pipeline of opportunities for Fund III.”

To learn more about Anzu Partners, please visit

About Anzu Partners
Anzu Partners is an investment firm that focuses on industrial and life science technology companies with the potential to transform their industries. Anzu works with entrepreneurs to develop and commercialize technological innovations by providing capital alongside deep expertise in business development, market positioning, global connectivity, and operations. For more information, please visit